Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression

Cellular senescence: when bad things happen to good cells

Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · see citing works

Mechanisms of type-I- and type-II-interferon-mediated signalling

Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,480 · see citing works

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works

The essence of senescence: Figure 1.

Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038 · see citing works

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · see citing works

Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication

Di Micco, R., Fumagalli, M., Cicalese, A., Piccinin, S., Gasparini, P., Luise, C., Schurra, C., Garre’, M., Giovanni Nuciforo, P., Bensimon, A., et al. (2006) · Nature · doi:10.1038/nature05327 · Cited by 1,821 · see citing works

High frequency of BRAF mutations in nevi

Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730 · see citing works

Inflammatory networks during cellular senescence: causes and consequences.

Freund, A., Orjalo, A. V., Desprez, P.-Y., & Campisi, J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.03.003 · Cited by 1,354 · see citing works

Type I interferons in anticancer immunity

Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305 · see citing works

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells

Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192 · see citing works

BrafV600E cooperates with Pten loss to induce metastatic melanoma

Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189 · see citing works

Interferons at age 50: past, current and future impact on biomedicine

Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154 · see citing works

Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7

Wajapeyee, N., Serra, R. W., Zhu, X., Mahalingam, M., & Green, M. R. (2008) · Cell · doi:10.1016/j.cell.2007.12.032 · Cited by 903 · see citing works

Cutaneous melanoma

Eggermont, A. M. M., Spatz, A., & Robert, C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60802-8 · Cited by 560 · see citing works

Immunotherapy of cancer in 2012

Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H. M., Kaliński, P., & Ferrone, S. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436 · see citing works

β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas

Damsky, W., Curley, D. P., Santhanakrishnan, M., Rosenbaum, L. E., Platt, J. T., Rothberg, B. E. G., Taketo, M. M., Dankort, D. L., Rimm, D. L., McMahon, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.030 · Cited by 351 · see citing works

Interferons in the treatment of human cancer.

Kirkwood, J. M., & Ernstoff, M. S. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.4.336 · Cited by 333 · see citing works

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

Zingg, D., Debbache, J., Schaefer, S. M., Tuncer, E., Frommel, S. C., Cheng, P. F., Arenas-Ramirez, N., Häusel, J., Zhang, Y., Bonalli, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7051 · Cited by 331 · see citing works

BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.

Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z. A., & Aaronson, S. A. (2003) · PubMed · Cited by 302 · see citing works

The Receptor of the Type I Interferon Family

Uzé, G., Schreiber, G., Piehler, J., & Pellegrini, S. (2007) · Springer eBooks · doi:10.1007/978-3-540-71329-6_5 · Cited by 262 · see citing works

DNA damage-induced type I interferon promotes senescence and inhibits stem cell function

Yu, Q., Katlinskaya, Y. V., Carbone, C. J., Zhao, B., Katlinski, K. V., Zheng, H., Guha, M., Li, N., Chen, Q., Yang, T., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.069 · Cited by 260 · see citing works

Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R. H., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256 · see citing works

DNA Damage Signaling and p53-dependent Senescence after Prolonged β-Interferon Stimulation

Moiseeva, O., Mallette, F. A., Mukhopadhyay, U. K., Moores, A., & Ferbeyre, G. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-09-0858 · Cited by 252 · see citing works

Impaired interferon signaling is a common immune defect in human cancer

Critchley-Thorne, R. J., Simons, D. L., Yan, N., Miyahira, A. K., Dirbas, F. M., Johnson, D. L., Swetter, S. M., Carlson, R. W., Fisher, G. A., Koong, A. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901329106 · Cited by 249 · see citing works

Structural and dynamic determinants of type <scp>I</scp> interferon receptor assembly and their functional interpretation

Piehler, J., Thomas, C., Garcia, K. C., & Schreiber, G. (2012) · Immunological Reviews · doi:10.1111/imr.12001 · Cited by 230 · see citing works

SCFHOS ubiquitin ligase mediates the ligand‐induced down‐regulation of the interferon‐α receptor

Kumar, S., Tang, W., Ravindranath, A. K., Clark, W. A., Croze, E., & Fuchs, S. Y. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg524 · Cited by 187 · see citing works

mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation

Damsky, W., Micevic, G., Meeth, K., Muthusamy, V., Curley, D. P., Santhanakrishnan, M., Erdelyi, I., Platt, J. T., Huang, L., Theodosakis, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.014 · Cited by 142 · see citing works

Phosphorylation and Specific Ubiquitin Acceptor Sites Are Required for Ubiquitination and Degradation of the IFNAR1 Subunit of Type I Interferon Receptor

Kumar, S., Krolewski, J. J., & Fuchs, S. Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407082200 · Cited by 142 · see citing works

Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma

Critchley-Thorne, R. J., Yan, N., Nacu, Ş., Weber, J. S., Holmes, S., & Lee, P. P. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040176 · Cited by 137 · see citing works

IFN-α in the Treatment of Melanoma

Tarhini, A. A., Gogas, H. J., & Kirkwood, J. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1290060 · Cited by 135 · see citing works

Virus-Induced Unfolded Protein Response Attenuates Antiviral Defenses via Phosphorylation-Dependent Degradation of the Type I Interferon Receptor

Liu, J., HuangFu, W., Kumar, K. G., Qian, J., Casey, J. P., Hamanaka, R. B., Grigoriadou, C., Aldabe, R., Diehl, J. A., & Fuchs, S. Y. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2008.11.008 · Cited by 135 · see citing works

Site-specific ubiquitination exposes a linear motif to promote interferon-α receptor endocytosis

Kumar, S., Barrière, H., Carbone, C. J., Liu, J., Swaminathan, G., Xu, P., Li, Y., Baker, D. P., Peng, J., Lukács, G. L., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200706034 · Cited by 135 · see citing works

Cutaneous melanoma in the era of molecular profiling

Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61397-0 · Cited by 134 · see citing works

The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells

Hou, P., Liu, D., Dong, J., & Xing, M. (2012) · Cell Cycle · doi:10.4161/cc.11.2.18707 · Cited by 91 · see citing works

Effects of interferon on differentiation of normal and tumor cells

Fisher, P. B., & Grant, S. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90067-1 · Cited by 86 · see citing works

Hope and Fear for Interferon: The Receptor-Centric Outlook on the Future of Interferon Therapy

Fuchs, S. Y. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2012.0117 · Cited by 80 · see citing works

Ligand-Stimulated Downregulation of the Alpha Interferon Receptor: Role of Protein Kinase D2

Zheng, H., Qian, J., Varghese, B., Baker, D. P., & Fuchs, S. Y. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01154-10 · Cited by 75 · see citing works

Vascular endothelial growth factor–induced elimination of the type 1 interferon receptor is required for efficient angiogenesis

Zheng, H., Qian, J., Carbone, C. J., Leu, N. A., Baker, D. P., & Fuchs, S. Y. (2011) · Blood · doi:10.1182/blood-2011-06-359745 · Cited by 74 · see citing works

Inflammatory signaling compromises cell responses to interferon alpha

HuangFu, W.-C., Qian, J., Liu, C., Liu, J., Lokshin, A. E., Baker, D. P., Rui, H., & Fuchs, S. Y. (2011) · Oncogene · doi:10.1038/onc.2011.221 · Cited by 71 · see citing works

The effect of environmental cues on the differentiation of myofibroblasts in peritoneal granulation tissue

(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70 · see citing works

Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses

Bhattacharya, S., HuangFu, W.-C., Dong, G., Qian, J., Baker, D. P., Karar, J., Koumenis, C., Diehl, J. A., & Fuchs, S. Y. (2012) · Oncogene · doi:10.1038/onc.2012.439 · Cited by 68 · see citing works

Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury

Bhattacharya, S., Katlinski, K. V., Reichert, M., Takano, S., Brice, A. K., Zhao, B., Yu, Q., Zheng, H., Carbone, C. J., Katlinskaya, Y. V., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303236 · Cited by 63 · see citing works

Melanoma: therapeutic options with recombinant interferons.

Kirkwood, J. M., & Ernstoff, M. S. (1985) · PubMed · Cited by 50 · see citing works

Role of p38 Protein Kinase in the Ligand-independent Ubiquitination and Down-regulation of the IFNAR1 Chain of Type I Interferon Receptor

Bhattacharya, S., Qian, J., Tzimas, C., Baker, D. P., Koumenis, C., Diehl, J. A., & Fuchs, S. Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.238766 · Cited by 48 · see citing works

Inducible Priming Phosphorylation Promotes Ligand-independent Degradation of the IFNAR1 Chain of Type I Interferon Receptor

Bhattacharya, S., HuangFu, W., Liu, J., Veeranki, S., Baker, D. P., Koumenis, C., Diehl, J. A., & Fuchs, S. Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.071498 · Cited by 45 · see citing works

IFNβ Produced by TLR4-Activated Tumor Cells Is Involved in Improving the Antitumoral Immune Response

Núñez, N. G., Andreani, V., Crespo, M. I., Nocera, D. A., Breser, M. L., Morón, G., Dejager, L., Libert, C., Rivero, V. E., & Maccioni, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0534 · Cited by 45 · see citing works

Pathogen Recognition Receptor Signaling Accelerates Phosphorylation-Dependent Degradation of IFNAR1

Qian, J., Zheng, H., HuangFu, W., Liu, J., Carbone, C. J., Leu, N. A., Baker, D. P., & Fuchs, S. Y. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002065 · Cited by 44 · see citing works

Transforming growth factor-β1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system

Ramont, L., Brassart‐Pasco, S., Hornebeck, W., Maquart, F., & Monboisse, J. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00336-7 · Cited by 41 · see citing works

Does interferon cure cancer?

Sikora, K. (1980) · BMJ · doi:10.1136/bmj.281.6244.855 · Cited by 35 · see citing works

Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells

Kumar, K. G., Liu, J., Li, Y., Yu, D., Thomas‐Tikhonenko, A., Herlyn, M., & Fuchs, S. Y. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4569 · Cited by 27 · see citing works

Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients

Simons, D. L., Lee, G., Kirkwood, J. M., & Lee, P. P. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-52 · Cited by 27 · see citing works

Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma

Hofmann, U. B., Eggert, A. A. O., Blass, K., Bröcker, E., & Becker, J. C. (2005) · Archives of Dermatological Research · doi:10.1007/s00403-005-0588-2 · Cited by 24 · see citing works

Interferon-alpha: current status and future promise.

Bonnem, E. M., & Rj, S. (1984) · PubMed · Cited by 21 · see citing works

mTOR Signaling in Melanoma: Oncogene-Induced Pseudo-Senescence?

Souroullas, G. P., & Sharpless, N. E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.005 · Cited by 11 · see citing works

Predictors of response to interferon therapy

Gogas, H. J., & Kirkwood, J. M. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328325317a · Cited by 9 · see citing works

Immunotherapy of Cancer

Davar, D., Tarhini, A. A., & Kirkwood, J. M. (2017) · doi:10.1002/9781119468868.ch20 · Cited by 9 · see citing works

Clinicopathological Characterization of Mouse Models of Melanoma

Ferguson, B., Soyer, H. P., & Walker, G. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2297-0_11 · Cited by 5 · see citing works

Cellular senescence in ageing: from mechanisms to therapeutic opportunities

Di Micco, R., Krizhanovsky, V., Baker, D., & d’Adda di Fagagna, F. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00314-w · Cited by 2,277 · see citing works

The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer

Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293 · see citing works

Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence

Glück, S., Guey, B., Gulen, M. F., Wolter, K., Kang, T.-W., Schmacke, N. A., Bridgeman, A., Rehwinkel, J., Zender, L., & Ablasser, A. (2017) · Nature Cell Biology · doi:10.1038/ncb3586 · Cited by 1,196 · see citing works

Linking cellular stress responses to systemic homeostasis

Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 529 · see citing works

Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity

Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity · doi:10.1016/j.immuni.2021.10.020 · Cited by 372 · see citing works

Small Extracellular Vesicles Are Key Regulators of Non-cell Autonomous Intercellular Communication in Senescence via the Interferon Protein IFITM3

Borghesan, M., Fafián-Labora, J., Eleftheriadou, O., Carpintero-Fernández, P., Paez-Ribes, M., Vizcay-Barrena, G., Swisa, A., Kolodkin-Gal, D., Ximénez-Embún, P., Lowe, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.095 · Cited by 315 · see citing works

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity

Gato, M., Zuazo, M., Arasanz, H., Ibáñez-Vea, M., de Lorenzo, L., Fernández-Hinojal, G., Vera, R., Smerdou, C., Martišová, E., Arozarena, I., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.075 · Cited by 310 · see citing works

The intracellular signalosome of PD-L1 in cancer cells

Escors, D., Gato, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. T. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 299 · see citing works

Cytosolic DNA Sensing in Organismal Tumor Control

Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250 · see citing works

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment

Katlinski, K. V., Gui, J., Katlinskaya, Y. V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C. J., Beiting, D. P., Girondo, M. A., Peck, A. R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.004 · Cited by 248 · see citing works

Melanocytic nevi and melanoma: unraveling a complex relationship

Damsky, W., & Bosenberg, M. (2017) · Oncogene · doi:10.1038/onc.2017.189 · Cited by 251 · see citing works

The molecular basis for differential type I interferon signaling

Schreiber, G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.774562 · Cited by 240 · see citing works

Cellular senescence: Molecular mechanisms and pathogenicity

Wei, W., & Ji, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26956 · Cited by 205 · see citing works

Opposing Roles of Type I Interferons in Cancer Immunity

Boukhaled, G. M., Harding, S. M., & Brooks, D. G. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-031920-093932 · Cited by 195 · see citing works

Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance

Budhwani, M., Mazzieri, R., & Dolcetti, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00322 · Cited by 174 · see citing works

Genomic instability, inflammatory signaling and response to cancer immunotherapy

Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166 · see citing works

NLRP3 inflammasome activation in inflammaging

Latz, E., & Duewell, P. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.001 · Cited by 174 · see citing works

An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles

Ortiz, A., Gui, J., Zahedi, F., Yu, P., Cho, C., Bhattacharya, S., Carbone, C. J., Yu, Q., Katlinski, K. V., Katlinskaya, Y. V., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.001 · Cited by 155 · see citing works

Type I and II Interferons in the Anti-Tumor Immune Response

Fenton, S. E., Saleiro, D., & Platanias, L. C. (2021) · Cancers · doi:10.3390/cancers13051037 · Cited by 138 · see citing works

Type I interferon and cancer

Holíček, P., Guilbaud, E., Klapp, V., Truxová, I., Špíšek, R., Galluzzi, L., & Fucikova, J. P. (2023) · Immunological Reviews · doi:10.1111/imr.13272 · Cited by 138 · see citing works

Extranuclear DNA accumulates in aged cells and contributes to senescence and inflammation

Lan, Y. Y., Heather, J. M., Eisenhaure, T., Garris, C. S., Lieb, D., Raychowdhury, R., & Hacohen, N. (2019) · Aging Cell · doi:10.1111/acel.12901 · Cited by 130 · see citing works

Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications

Aricò, E., Castiello, L., Capone, I., Gabriele, L., & Belardelli, F. (2019) · Cancers · doi:10.3390/cancers11121943 · Cited by 129 · see citing works

Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway

Alicea-Torres, K. M., Sanseviero, E., Gui, J., Chen, J., Veglia, F., Yu, Q., Donthireddy, L., Kossenkov, A. V., Lin, C., Fu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22033-2 · Cited by 123 · see citing works

Roles of the cGAS-STING Pathway in Cancer Immunosurveillance and Immunotherapy

Yum, S., Li, M., Frankel, A. E., & Chen, Z. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055636 · Cited by 108 · see citing works

Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses

Matveeva, O. V., & Chumakov, P. M. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.2008 · Cited by 105 · see citing works

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86 · see citing works

Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming

Torrano, J., Emran, A. A., Hammerlindl, H., & Schaider, H. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0644-y · Cited by 85 · see citing works

Alzheimer’s disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model

Carling, G. K., Fan, L., Foxe, N. R., Norman, K., Wong, M. Y., Zhu, D., Corona, C., Razzoli, A., Yu, F., Yarahmady, A., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.09.006 · Cited by 89 · see citing works

miR-93-5p/IFNAR1 axis promotes gastric cancer metastasis through activating the STAT3 signaling pathway

Ma, D.-H., Li, B., Liu, J., Xiao, Y., Yong, X., Wang, S.-M., Wu, Y., Zhu, H., Wang, D., & Yang, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.017 · Cited by 82 · see citing works

Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

Brockwell, N. K., Owen, K. L., Zanker, D. J., Spurling, A., Rautela, J., Duivenvoorden, H. M., Baschuk, N., Caramia, F., Loi, S., Darcy, P. K., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0150 · Cited by 83 · see citing works

Role of Type I and II Interferons in Colorectal Cancer and Melanoma

Franco, S. D., Turdo, A., Todaro, M., & Stassi, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00878 · Cited by 74 · see citing works

Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs

Gui, J., Zahedi, F., Ortiz, A., Cho, C., Katlinski, K. V., Alicea-Torres, K. M., Li, J., Todd, L., Zhang, H., Beiting, D. P., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0064-0 · Cited by 69 · see citing works

IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment

Elcheva, I. A., Gowda, C. P., Bogush, D., Gornostaeva, S., Fakhardo, A., Sheth, N., Kokolus, K. M., Sharma, A., Dovat, S., Uzun, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224516 · Cited by 66 · see citing works

Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma

Sood, S., Jayachandiran, R., & Pandey, S. (2021) · Integrative Cancer Therapies · doi:10.1177/1534735421990078 · Cited by 56 · see citing works

Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases

Ng, J. C.-F., Quist, J., Grigoriadis, A. E., Malim, M. H., & Fraternali, F. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1316 · Cited by 54 · see citing works

Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice

Zemek, R. M., Chin, W. L., Fear, V. S., Wylie, B., Casey, T. H., Forbes, C., Tilsed, C. M., Boon, L., Guo, B. B., Bosco, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32567-8 · Cited by 48 · see citing works

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45 · see citing works

Response of human macrophages to gamma radiation is mediated via expression of endogenous retroviruses

Mikhalkevich, N., O’Carroll, I. P., Tkavc, R., Lund, K., Sukumar, G., Dalgard, C. L., Johnson, K. R., Li, W., Wang, T., Nath, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009305 · Cited by 41 · see citing works

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC

Brockwell, N. K., Rautela, J., Owen, K. L., Gearing, L. J., Deb, S., Harvey, K., Spurling, A., Zanker, D. J., Chan, C., Cumming, H. E., et al. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0093-2 · Cited by 41 · see citing works

cGAS and cancer therapy: a double-edged sword

Du, J., Qian, M., Yuan, T., Chen, R., He, Q., Yang, B., Ling, Q., & Zhu, H. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00839-6 · Cited by 39 · see citing works

Changes in the biochemical taste of cytoplasmic and cell-free DNA are major fuels for inflamm-aging

Storci, G., Carolis, S. D., Olivieri, F., & Bonafè, M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.08.003 · Cited by 37 · see citing works

Harnessing type I interferon-mediated immunity to target malignant brain tumors

Lim, J., Kang, I., La, J., Ku, K. B., Kang, B. H., Kim, Y., Park, W. H., & Lee, H. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203929 · Cited by 35 · see citing works

An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation

Castiello, L., Zevini, A., Vulpis, E., Muscolini, M., Ferrari, M., Palermo, E., Peruzzi, G., Krapp, C., Jakobsen, M. R., Olagnier, D. P., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02380-2 · Cited by 32 · see citing works

Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis

Cho, C., Mukherjee, R., Peck, A. R., Sun, Y., McBrearty, N., Katlinski, K. V., Gui, J., Govindaraju, P. K., Puré, E., Rui, H., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01424-7 · Cited by 32 · see citing works

Reduced RNA turnover as a driver of cellular senescence

Mullani, N., Porozhan, Y., Mangelinck, A., Rachez, C., Costallat, M., Batsché, É., Goodhardt, M., Cenci, G., Mann, C., & Muchardt, C. (2021) · Life Science Alliance · doi:10.26508/lsa.202000809 · Cited by 33 · see citing works

The pleiotropic roles of cGAS–STING signaling in the tumor microenvironment

Li, J., & Bakhoum, S. F. W. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac019 · Cited by 29 · see citing works

Age-Dependent Effects of Type I and Type III IFNs in the Pathogenesis of Bordetella pertussis Infection and Disease

Ardanuy, J., Scanlon, K. M., Skerry, C. M., Fuchs, S. Y., & Carbonetti, N. H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900912 · Cited by 30 · see citing works

IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion?

Araya, R. E., & Goldszmid, R. S. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.012 · Cited by 27 · see citing works

Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer

Zanker, D. J., Owen, K. L., Baschuk, N., Spurling, A., & Parker, B. S. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02857-z · Cited by 24 · see citing works

Regulation of intercellular biomolecule transfer–driven tumor angiogenesis and responses to anticancer therapies

Lu, Z. F., Ortiz, A., Verginadis, I. I., Peck, A. R., Zahedi, F., Cho, C., Yu, P., DeRita, R. M., Zhang, H., Kubanoff, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144225 · Cited by 23 · see citing works

Tumor inherent interferons: Impact on immune reactivity and immunotherapy

Brockwell, N. K., & Parker, B. S. (2018) · Cytokine · doi:10.1016/j.cyto.2018.04.006 · Cited by 21 · see citing works

Oncolytic Virotherapy: The Cancer Cell Side

Ehrlich, M., & Bacharach, E. (2021) · Cancers · doi:10.3390/cancers13050939 · Cited by 23 · see citing works

A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon

Zhang, K.-J., Yin, X., Yang, Y., Li, H., Xu, Y., Chen, L.-Y., Liu, X.-J., Yuan, S., Fang, X.-L., Xiao, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1386 · Cited by 20 · see citing works

Oncogenic KIT Modulates Type I IFN–Mediated Antitumor Immunity in GIST

Liu, M., Etherington, M. S., Hanna, A. N., Medina, B. D., Vitiello, G. A., Bowler, T. G., Param, N. J., Levin, L. I., Rossi, F., & DeMatteo, R. P. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0692 · Cited by 19 · see citing works

The FOXC2 Transcription Factor Promotes Melanoma Outgrowth and Regulates Expression of Genes Associated With Drug Resistance and Interferon Responsiveness

Hargadon, K. M., Győrffy, B., Strong, E. W., TARNAI, B. D., Thompson, J., Bushhouse, D. Z., Johnson, C. E., & Williams, C. J. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20152 · Cited by 18 · see citing works

The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications

Hargadon, K. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20608 · Cited by 18 · see citing works

CRISPR activation screen in mice identifies novel membrane proteins enhancing pulmonary metastatic colonisation

van der Weyden, L., Harle, V. J., Turner, G., Offord, V., Iyer, V., Droop, A., Świątkowska, A., Rabbie, R., Campbell, A. D., Sansom, O. J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01912-w · Cited by 18 · see citing works

Senescence of human pancreatic beta cells enhances functional maturation through chromatin reorganization and promotes interferon responsiveness

Patra, M., Klochendler, A., Condiotti, R., Kaffe, B., Elgavish, S., Drawshy, Z., Avrahami, D., Narita, M., Hofree, M., Drier, Y., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae313 · Cited by 18 · see citing works

Cellular Senescence and Ageing

Reed, R., & Miwa, S. (2023) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-21410-3_7 · Cited by 16 · see citing works

A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma

Gureghian, V., Herbst, H., Kozar, I., Mihajlović, K., Malod‐Dognin, N., Ceddia, G., Angeli, C., Margue, C., Randic, T., Philippidou, D., et al. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00640-z · Cited by 16 · see citing works

Interferon-driven Metabolic Reprogramming and Tumor Microenvironment Remodeling

Chang, T.-H., & Ho, P. (2025) · Immune Network · doi:10.4110/in.2025.25.e8 · Cited by 17 · see citing works

MX 2 is a novel regulator of cell cycle in melanoma cells

Juraleviciute, M., Poźniak, J., Nsengimana, J., Harland, M., Randerson‐Moor, J. A., Wernhoff, P., Bassarova, A. V., Øy, G. F., Trøen, G., Flørenes, V. A., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12837 · Cited by 15 · see citing works

Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers

Odnokoz, O., Yu, P., Peck, A. R., Sun, Y., Kovatich, A. J., Hooke, J. A., Hu, H., Mitchell, E. P., Rui, H., & Fuchs, S. Y. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1750297 · Cited by 16 · see citing works

Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies

Gao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 16 · see citing works

MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell–intrinsic Amplification of Type I IFN Signaling

Ghukasyan, R., Liang, K., Chau, K., Li, L., Chan, C., Abt, E. R., Le, T. M., Park, J. Y., Wu, N., Premji, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3322 · Cited by 14 · see citing works

Retrotransposons in Werner syndrome-derived macrophages trigger type I interferon-dependent inflammation in an atherosclerosis model

Paul, S. K., Oshima, M., Patil, A., Sone, M., Kato, H., Maezawa, Y., Kaneko, H., Fukuyo, M., Rahmutulla, B., Ouchi, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48663-w · Cited by 15 · see citing works

Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment

Zhang, H., Tomar, V. S., Li, J., Basavaraja, R., Yan, F., Gui, J., McBrearty, N., Costich, T. L., Beiting, D. P., Blanco, M. A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0295 · Cited by 13 · see citing works

Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus

Dellac, S., Ben‐Dov, H., Raanan, A., Saleem, H., Zamostiano, R., Semyatich, R., Lavi, S., Witz, I. P., Bacharach, E., & Ehrlich, M. (2020) · International Journal of Cancer · doi:10.1002/ijc.33401 · Cited by 12 · see citing works

Intracellular signaling modules linking DNA damage to secretome changes in senescent melanoma cells

Chavanet, A., Hill, K. R., Jiménez-Andrade, Y., Choo, M., White, K., & Park, J. M. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000671 · Cited by 11 · see citing works

Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy

Ladányi, A., Rásó, E., Barbai, T., Vízkeleti, L., Puskás, L. G., Kovacs, S., Győrffy, B., & Tı́már, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052704 · Cited by 11 · see citing works

The proteomic study of serially passaged human skin fibroblast cells uncovers down-regulation of the chromosome condensin complex proteins involved in replicative senescence

Meng, Q., Gao, J., Zhu, H., He, H., Lu, Z. H., Hong, M., & Zhou, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.065 · Cited by 10 · see citing works

Genetic Programs Driving Oncogenic Transformation: Lessons from In Vitro Models

Giorgio, E. D., Paluvai, H., Picco, R., & Brancolini, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246283 · Cited by 10 · see citing works

Innate immunity of the gut epithelium: Blowing in the WNT?

de Vries, M. H., Kuijk, E., & Nieuwenhuis, E. E. S. (2025) · Mucosal Immunology · doi:10.1016/j.mucimm.2025.06.004 · Cited by 9 · see citing works

Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma

Kuras, M., Betancourt, L. H., Hong, R., Szadai, L., Murillo, J. R., Horvatovich, P. L., Plá, I., Eriksson, J. O., Szeitz, B., Deszcz, B., et al. (2025) · Cancers · doi:10.3390/cancers17050832 · Cited by 8 · see citing works

Striking the right balance with type I interferon signalling in cancer

Chadwick, T. B., So, J., Hertzog, P. J., Haynes, N. M., & Parker, B. S. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00915-1 · Cited by 9 · see citing works

Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-β Autocrine Stimulation

Solomon, P. E., Kirkemo, L. L., Wilson, G. M., Leung, K., Almond, M. H., Sayles, L. C., Sweet-Cordero, A., Rosenberg, O. S., Coon, J. J., & Wells, J. A. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100247 · Cited by 8 · see citing works

Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+ T cell-dependent immune response

Liu, J., Hu, Y.-Y., Zhang, Q., Zhang, Y., Li, N., Zhang, Z., Zhan, S., Gao, L., Deng, C., Li, X., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114094 · Cited by 8 · see citing works

NUPR1 packaged in extracellular vesicles promotes murine triple-negative breast cancer in a type 1 interferon-independent manner

Ortiz, A., Stavrou, A., Liu, S., Chen, D., Shen, S. S., & Jin, C. (2024) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.59 · Cited by 7 · see citing works

Significance of exosomes in hepatocellular carcinoma

Wang, G., Luo, G., Zhao, M., & Miao, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1056379 · Cited by 7 · see citing works

A cyclin D-CDK6 dimer helps to reshuffle cyclin-dependent kinase inhibitors (CKI) to overcome TGF-beta-mediated arrest and maintain CDK2 activity

Nataraj, S. E., & Blain, S. W. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1909261 · Cited by 6 · see citing works

Polyvinylpyrrolidone-Polydatin nanoparticles protect against oxaliplatin induced intestinal toxicity in vitro and in vivo

Zhou, S., Sun, Y., Wang, K., Gao, X., Dong, K., Wang, J., Wu, X., & Guo, C. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.114427 · Cited by 6 · see citing works

Selective Antitumor Effect of Shikonin Derived DMAKO-20 on Melanoma through CYP1B1

Cui, J., Zhou, X., Huang, J., Cui, J., & Chen, J. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666201116112937 · Cited by 6 · see citing works

Enhanced IFN Sensing by Aggressive Chronic Lymphocytic Leukemia Cells

Luo, T. Y., Shi, Y., Wang, G., & Spaner, D. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200199 · Cited by 6 · see citing works

Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors

Yan, H., Wang, Y., Zhu, M., Sun, D., Li, H., & Chen, L. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115555 · Cited by 5 · see citing works

Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma

Vízkeleti, L., Papp, O., Doma, V., Gil, J., Marko‐Varga, G., Kovacs, S., Győrffy, B., Kárpáti, S., & Tı́már, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-77285-x · Cited by 4 · see citing works

A case of malignant melanoma with multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy

Fukumoto, T., Fujiwara, S., Sakaguchi, M., Oka, M., & Nishigori, C. (2018) · European Journal of Dermatology · doi:10.1684/ejd.2017.3169 · Cited by 4 · see citing works

Histopathology-assisted proteogenomics provides foundations for stratification of melanoma metastasesPreprint

Kuras, M., Betancourt, L. H., Hong, R., Szadai, L., Murillo, J. R., Horvatovich, P. L., Plá, I., Eriksson, J. O., Szeitz, B., Deszcz, B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.29.559755 · Cited by 4 · see citing works

Elimination of senescent cells with senolytic host-directed therapy reduces tuberculosis progression in micePreprint

Shee, S., Martinez-Martinez, Y. B., Koleske, B. N., Yabaji, S. M., Kobzik, L., Kramnik, I., & Bishai, W. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.28.645957 · Cited by 4 · see citing works

Cancer Cell-Intrinsic Type I Interferon Signaling Promotes Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Xie, G., Yang, C., Pang, X., Wu, T.-C., & Gu, X. (2025) · Cancers · doi:10.3390/cancers17081279 · Cited by 4 · see citing works

Pasta, a Versatile Transcriptomic Clock, Maps the Chemical and Genetic Determinants of Aging and Rejuvenation

Salignon, J., Tsiokou, M., Marqués, P., Rodríguez-Diaz, E., Ang, H. X., Pietrocola, F., & Riedel, C. G. (2026) · Advanced Science · doi:10.1002/advs.76740 · Cited by 4 · see citing works

cJun-N-terminal kinase activity and mitosis perturbation drive the 2-methoxyestradiol-mediated enhancement of viral oncolysis by Epizootic Hemorrhagic Disease Virus-Tel Aviv University

De, S., Kashkash, S., Bozhdansky, V., Bacharach, E., & Ehrlich, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-08687-8 · Cited by 2 · see citing works

Pre‐Encoded IFN‐I Sensitivity Exacerbates Memory T Cell Senescence in Solid Tumors

Nguyen, A., Walsh, S. R., Deng, L., Chen, L., & Wan, Y. (2025) · Advanced Science · doi:10.1002/advs.202504474 · Cited by 2 · see citing works

Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy

De, S., & Ehrlich, M. (2024) · Genes · doi:10.3390/genes15091193 · Cited by 2 · see citing works

Senescence-associated and immune-related 9p21.3 locus genes in colorectal cancer: epigenetic architecture, molecular landscape and therapeutic possibilities

Lisitsa, D. A., Shindyapin, V. V., Nurislamov, A. R., Demidov, O. N., & Bogdanova, D. A. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1741704 · Cited by 1 · see citing works

Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia

Zhao, B., Bhattacharya, S., Yu, Q., & Fuchs, S. Y. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1319053 · Cited by 1 · see citing works

Combination of nanosomal form of doxorubicin, interferon alpha, and nitroglycerin in the threatment of 101.8 glioblastoma in Wistar rats

Kudelkina, V. V., Khalansky, A. S., Алексеева, А. И., Gorelikov, P. L., & Kosyreva, A. M. (2022) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2021-66-9-10-17-23 · Cited by 1 · see citing works

An in vivo and in vitro study of stress-induced senescence in neurones and its role in neurodegeneration

Vázquez-Villaseñor, I. (2018) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)

Overcoming immune checkpoint inhibitors resistance using oncolytic viruses in melanoma

Nguyen, T. T. (2020) · doi:10.82308/33882

Faculty Opinions recommendation of Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence.

Muehlich, S., & Mittermeier, C. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727857070.793537467

Senescence induction in human melanoma by the combined action of type II interferon and tumor necrosis factor.

Boß, C. N., Kayser, S., Garbe, C., Feuchtinger, T. F., & Röcken, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.e22213

Abstract A63: IFNAR1 downregulation during melanoma progression upregulates αv expression and promotes metastasis

Ortiz, A., Katlinskaya, Y. V., Katlinski, K. V., & Fuchs, S. Y. (2016) · Cancer Research · doi:10.1158/1538-7445.tummet15-a63

Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade

Holzgruber, J., Martins, C. P., Kulcsár, Z., Duplaine, A., Rasbach, E., Migayron, L., Singh, P. K., Statham, E., Landsberg, J., Boniface, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51496-2 · Cited by 60 · see citing works

Tumor-suppressive effects of natural-type interferon-β through CXCL10 in melanoma

小林, 光. (2016) · Institutional Repositories DataBase (IRDB)

646 IFN-α therapy of peritoneal carcinosis induces senescence in metastatic melanoma cells

Brenner, E., Wieder, T., Braumüller, H., Boß, C. N., Schulz, C., Kayser, S., & Röcken, M. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.03.653